Zyrtec OTC, New Segments Picked Up From Pfizer Will Be Key Drivers – J&J
This article was originally published in The Tan Sheet
Johnson & Johnson is optimistic about potential earnings from an anticipated OTC launch of Zyrtec (cetirizine HCl) allergy medication late in 2007, company Chairman and CEO William C. Weldon said during a Jan. 23 conference call on the firm's 2006 fourth-quarter and full-year earnings
You may also be interested in...
The past year offered anticipated changes and moves as well as some unexpected thrills and chills for the nonprescription drugs and nutritional products industries
FDA approved Johnson & Johnson's bid to switch prescription antihistamine/nasal decongestant Zyrtec-D to nonprescription status, but the firm is still awaiting a reply on single-ingredient Zyrtec
Last year's acquisition of Pfizer's Consumer Healthcare unit drove Johnson & Johnson's consumer products segment revenue and increased the proportion of international sales in OTCs and nutritionals